Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Silence Therapeutics, Oxford, Sigma, Alnylam

Premium
Santaris Receives Grant to Develop miRNA-Targeting Drug
 
Santaris Pharma said this week that it has received a €1.35 million ($1.8 million) grant from the Danish National Advanced Technology Foundation to develop SPC3649, a locked nucleic acid-based drug that targets the microRNA miR-122.
 
Although Santaris has used the LNA agent to cut cholesterol levels in animal models, the company has said it expects to develop it as a treatment for hepatitis C (see RNAi News, 5/24/2007).
 
Santaris said this is the second such grant it has received. In 2006, the ATF awarded the company a €1.3 million grant to fund its miRNA therapeutics programs.
 

 
Silence Reports Higher Revenues, Costs in 2006
 
Silence Therapeutics, formerly SR Pharma, last week reported its financial results for 2006, the first full year for which its finances are being reported since it acquired German RNAi drugs shop Atugen (see RNAi News 7/29/2005).
 
Silence’s revenues in 2006 climbed to ₤1.95 million ($4 million) from ₤510,000 the year before, a jump largely due to money received through the company’s licensing arrangement with Quark Pharmaceuticals (see RNAi News, 3/18/2005).
 
Research and development spending in 2006 nearly doubled to ₤3.19 million from ₤1.66 million the year before, while administrative costs jumped to ₤3.03 million from ₤2.75 million. Silence noted that, having acquired Atugen in the middle of 2005, figures from that year only include six months of costs related to its German operations.
 
In 2006, Silence’s net loss was ₤4.27 million, compared with ₤3.9 million in 2005, and includes a number of non-cash items including depreciation and amortization.
 
As of Dec. 31, 2006, Silence had cash and cash equivalents totaling ₤8.8 million.
 

 
Oxford, Sigma Lentivirus Technology Licensed to US Biotech
 
Oxford BioMedica and Sigma-Aldrich said this week that they have signed a deal providing access to their LentiVector gene-delivery technology to an undisclosed, US-based biotech firm.
 
Additional terms of the arrangement were not disclosed.
 
Sigma-Aldrich is the exclusive licensee of the lentiviral technology, which was developed by Oxford BioMedica, for research applications.
 

 
Alnylam Says Nasdaq Compliance Regained Following ‘Inadvertent’ Stock Option Grant
 
Alnylam Pharmaceuticals last week said that it had been temporarily out of compliance with a Nasdaq exchange audit committee independence listing requirement.
 
According to Alnylam, it has since regained compliance and is not required to make changes to the composition of its audit committee.
 
The company said it was notified about the issue in a letter from Nasdaq regarding an inadvertent stock option grant by Alnylam to a member of its audit committee.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.